For at nedsætte risikoen for tumorlysesyndrom hos CLL patienter bør der gives forebyggende behandling med adækvat hydrering og administration af urikosurika 48 timer før behandlingens start.
Prophylaxis with adequate hydration and administration of uricostatics starting 48 hours prior to start of therapy is recommended for CLL patients to reduce the risk of tumour lysis syndrome.